Pfizer Inc. $PFE Shares Purchased by CORDA Investment Management LLC.

Key Points

• CORDA Investment Management increased its Pfizer stake by 5.2% in the first quarter, buying 59,130 more shares and bringing its holdings to 1,188,027 shares worth about $33.36 million.
• Pfizer is seeing mixed analyst sentiment: Bank of America cut its price target to $26 and kept a neutral rating, while the broader consensus remains Hold with an average target price of $28.56.
• Recent headlines were more positive for the pipeline, including FDA approval of PADCEV plus Keytruda for muscle-invasive bladder cancer, even as some market commentary continued to question Pfizer’s near-term growth outlook.

CORDA Investment Management LLC. boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 5.2% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,188,027 shares of the biopharmaceutical company's stock after buying an additional 59,130 shares during the quarter. Pfizer makes up about 2.3% of CORDA Investment Management LLC.'s holdings, making the stock its 22nd biggest position. CORDA Investment Management LLC.'s holdings in Pfizer were worth $33,360,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its position in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after buying an additional 6,415 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company's stock valued at $63,889,000 after buying an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC grew its stake in Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company's stock worth $2,480,000 after acquiring an additional 31,896 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Guggenheim raised their price objective on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday, March 24th. UBS Group reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. Finally, Wolfe Research reiterated an "underperform" rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.56.

Pfizer Price Performance

PFE opened at $24.21 on Monday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a 50 day moving average of $25.37 and a two-hundred day moving average of $26.19. The company has a market cap of $138.01 billion, a P/E ratio of 18.48 and a beta of 0.35. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. During the same period in the prior year, the company earned $0.92 EPS. The firm's revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer's dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.